We are experiencing some temporary issues. The market data on this page are currently delayed. Please bear with us as we address this and restore your personalized lists.
S&P Futures
3,350.00-2.75(-0.08%)Dow Futures
27,668.00-11.00(-0.04%)Nasdaq Futures
11,070.75-1.25(-0.01%)
Jazz Pharmaceuticals plc (JAZZ)
126.43 +0.08 (0.07%)
After hours: 4:11PM EDT
Chart Events
Performance Outlook
| Previous Close | 126.08 |
| Open | 126.19 |
| Bid | 123.58 x 800 |
| Ask | 127.55 x 800 |
| Day's Range | 125.18 - 127.45 |
| 52 Week Range | 86.88 - 154.24 |
| Volume | 502,666 |
| Avg. Volume | 701,523 |
| Market Cap | 7.007B |
| Beta (5Y Monthly) | 1.19 |
| PE Ratio (TTM) | 53.63 |
| EPS (TTM) | 2.36 |
| Earnings Date | Nov 03, 2020 - Nov 09, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 163.59 |
Fair Value
Related Research
- Zacks
Jazz Pharma (JAZZ) Beats on Q2 Earnings & Sales, Raises View
Jazz Pharmaceuticals (JAZZ) reports better-than-expected second-quarter 2020 earnings and revenues. It raises its guidance for 2020. Shares rise.
- Motley Fool
What's Behind Jazz Pharmaceuticals' Q2 Revenue and Earnings Beats
Jazz Pharmaceuticals (NASDAQ: JAZZ) hasn't given investors much good news so far in 2020. The drugmaker's first-quarter results announced in May were disappointing. Jazz stock has dropped 23% year to date.
- Zacks
Jazz Pharmaceuticals (JAZZ) Q2 Earnings and Revenues Beat Estimates
Jazz (JAZZ) delivered earnings and revenue surprises of 9.76% and 11.06%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
Jazz Pharmaceuticals Announces Second Quarter 2020 Financial Results
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the second quarter of 2020 and updated its 2020 financial guidance.
- Benzinga
Preview: Jazz Pharmaceuticals's Earnings
Jazz Pharmaceuticals (NASDAQ: JAZZ) announces its next round of earnings this Tuesday, August 04. Here is Benzinga's everything-that-matters guide for this Tuesday's Q2 earnings announcement.Earnings and Revenue Based on management's projections, Jazz Pharmaceuticals analysts model for earnings of $3.13 per share on sales of $501.95 million. In the same quarter last year, Jazz Pharmaceuticals reported EPS of $4.050 on revenue of $534.13 million. If the company were to report in-line earnings when it publishes results Tuesday, earnings would be down 22.72%. Revenue would have fallen 7.66% from the same quarter last year. Here's how the company's EPS has stacked up against analyst estimates in the past:Quarter Q1 2020 Q4 2020 Q3 2019 Q2 2019 EPS Estimate 0.67 4.12 3.59 3.58 EPS Actual 0.45 4.42 4.10 4.05 Revenue Estimate 543.59 M 561.69 M 525.16 M 508.83 M Revenue Actual 534.73 M 581.74 M 537.70 M 534.13 M Stock Performance Over the last 52-week period, shares are down 22.75%. Given that these returns are generally negative, long-term shareholders are probably down going into this earnings release.View more earnings on JAZZDon't be surprised to see the stock move on comments made during its conference call. Jazz Pharmaceuticals is scheduled to hold the call at 16:30:00 ET and can be accessed here: https://edge.media-server.com/mmc/p/nxixrvtiSee more from Benzinga * Looking Into Texas Roadhouse's Return On Capital Employed * ROCE Insights For Hyatt Hotels * ROCE Insights For CVR Energy(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- Investopedia
10 Biggest Biotechnology Companies
With Novo Nordisk at the top of the list, these are the 10 biggest biotechnology companies by 12-month trailing revenue.
- Zacks
Analysts Estimate Jazz Pharmaceuticals (JAZZ) to Report a Decline in Earnings: What to Look Out for
Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Motley Fool
Jazz Pharmaceuticals Wins FDA Approval for Its New Narcolepsy Drug
Xywav has been shown to reduce both cataplexy and excessive daytime sleepiness in narcolepsy patients.
- Simply Wall St.
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Insiders Increased Their Holdings
It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...
- PR Newswire
Jazz Pharmaceuticals Announces U.S. FDA Approval of Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Cataplexy or Excessive Daytime Sleepiness Associated with Narcolepsy
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) approved Xywav™ (calcium, magnesium, potassium, and sodium oxybates) oral solution on July 21, 2020 for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy.1,2 Xywav is an oxybate product with a unique composition of cations resulting in 92 percent less sodium – or approximately 1,000 to 1,500 mg/night – than sodium oxybate at the recommended dosage range of 6 to 9 grams.1
Analyst Price Targets (17)
Upgrades & Downgrades
| Upgrade | Wolfe Research: Peer Perform to Outperform | 7/28/2020 | |
| Upgrade | HC Wainwright & Co.: Neutral to Buy | 7/23/2020 | |
| Maintains | B of A Securities: to Buy | 6/18/2020 | |
| Maintains | SVB Leerink: to Outperform | 6/1/2020 | |
| Maintains | SunTrust Robinson Humphrey: to Buy | 5/6/2020 | |
| Maintains | BMO Capital: to Outperform | 5/6/2020 |
